Tenderwize
Zurück zur Suche

Medicinal product with active ingredient combination Oxycodone and Naloxone (ATC: N02AA55)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2028 · 582 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Oxycodon und Naloxon (ATC: N02AA55)

25/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

25 / 100

Komplexität

10 / 100

Risikofaktoren

The notice explicitly states it is not a public procurement, so bidders do not have the usual legal protections (e.g...

No estimated volume or value provided; actual discounts and demand are unknown. The contract may yield minimal commerci...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of medicinal products containing oxycodone and naloxone (ATC: N02AA55) under non-exclusive discount agreements.
  • Open-house model: any eligible pharmaceutical company can join at any time without competitive procedure.
Vollständige Zusammenfassung anzeigen

This is an open-house model for non-exclusive discount agreements (Rabattverträge) under § 130a Abs. 8 SGB V for fixed-dose combination medicinal products containing oxycodone and naloxone (ATC: N02AA55). The buyer, AOK Sachsen-Anhalt, invites any eligible pharmaceutical company to join at any time on identical terms. The contract runs maximum 24 months starting from 01.05.2026 to 30.04.2028. The notice explicitly states it is not a public procurement under EU law and uses an 'open procedure' form only for publication. No estimated value, award criteria, or detailed eligibility criteria are provided. Participation documents must be requested from the buyer.

Risiken

The notice explicitly states it is not a public procurement, so bidders do not have the usual legal protections (e.g...

No estimated volume or value provided; actual discounts and demand are unknown. The contract may yield minimal commerci...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Must be a pharmaceutical company or consortium of pharmaceutical companies eligible under § 130a Abs. 8 SGB V.

Administrative

  • Must request participation documents from the buyer and submit them fully completed and signed.
  • Contract sign-off via electronic submission with qualified electronic signature or postal mail.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Medicinal product with active ingredient combination Oxycodone and Naloxone (ATC: N02AA55)

Non-exclusive discount agreements for finished medicinal products with oxycodone/naloxone combination (ATC: N02AA55). Participation open at any time; no exclusivity. Contract duration max 24 months, earliest start 01.05.2026, end 30.04.2028. If the buyer later tenders exclusive contracts, open-house agreements will be terminated accordingly.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Frist

Deadline Mar 30, 2028

Vergabedetails

Veröffentlichungsdatum
01 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
144037-2026

Dokumente (1)

Ähnliche Ausschreibungen